SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1421)11/13/1998 10:41:00 AM
From: Mr. Miller  Read Replies (2) | Respond to of 2135
 
The only confirmation is in journals. The WSJ or NYT or any other periodical that is not a scientific journal is worthless to the scientific community. However, wallstreet loves this stuff, so I guess that is what is driving this price, as it does with any other. Wallstreet will always be stupid to science.

The NYT "confirming" is a laugh.

Miller



To: Biomaven who wrote (1421)11/13/1998 11:44:00 AM
From: David Bogdanoff  Respond to of 2135
 
To all;

If Folkman's results are so hard (if at all possible) to duplicate in research laboratories, what are the prospects for mass commercialization of the therapy? It becomes like witch-doctor medicine; it actually works it is only in the hands of one person.

David


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News